Fig. 6: Clec9a-mediated CTL priming and antitumor immunity. | npj Vaccines

Fig. 6: Clec9a-mediated CTL priming and antitumor immunity.

From: Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials

Fig. 6

It illustrates the process by which antigens targeted to Clec9a on DCs are internalized and presented on MHC class I to CD8+ T cells, leading to their priming and differentiation into CTLs. Following activation, CTLs engage and destroy tumor cells via CTL-mediated direct killing (Granzyme, Perforin and Fas/Fas-L) and indirect killing (TNF-α and IFN-γ). Created with Figdraw.com.

Back to article page